Welcome to CDC Stacks | Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months - 7439 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months
  • Published Date:
    June 26, 2009
  • Status:
    retired
  • Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(24):673-4.
Filetype[HTML - ]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; American Academy of Family Physicians. ; American Academy of Pediatrics.
  • Description:
    On December 13, 2007, certain lots of Haemophilus influenzae type b (Hib) vaccine marketed as PedvaxHIB (monovalent Hib vaccine) and Comvax (Hib-HepB vaccine), and manufactured by Merck & Co., Inc., were recalled voluntarily, and the company temporarily suspended production of these vaccines. To conserve the limited supply of Hib-containing vaccines, CDC, in consultation with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), and the American Academy of Pediatrics (AAP), on December 18, 2007, recommended that vaccination providers temporarily defer the routine Hib vaccine booster dose administered to most healthy children at age 12-15 months

  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: